Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Total Debt: 2011-2025

Historic Total Debt for Abeona Therapeutics (ABEO) over the last 7 years, with Sep 2025 value amounting to $19.8 million.

  • Abeona Therapeutics' Total Debt rose 5.90% to $19.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.8 million, marking a year-over-year increase of 5.90%. This contributed to the annual value of $19.0 million for FY2024, which is N/A change from last year.
  • Abeona Therapeutics' Total Debt amounted to $19.8 million in Q3 2025, which was up 0.97% from $19.6 million recorded in Q2 2025.
  • Abeona Therapeutics' Total Debt's 5-year high stood at $34.4 million during Q2 2021, with a 5-year trough of $4.2 million in Q4 2022.
  • Moreover, its 2-year median value for Total Debt was $19.0 million (2024), whereas its average is $18.9 million.
  • In the last 5 years, Abeona Therapeutics' Total Debt grew by 21.94% in 2021 and then tumbled by 74.73% in 2022.
  • Over the past 4 years, Abeona Therapeutics' Total Debt (Quarterly) stood at $8.4 million in 2021, then slumped by 50.60% to $4.2 million in 2022, then reached $19.0 million in 2024, then increased by 5.90% to $19.8 million in 2025.
  • Its Total Debt was $19.8 million in Q3 2025, compared to $19.6 million in Q2 2025 and $19.3 million in Q1 2025.